IGM Biosciences banks a $103M megaround on its quest to pioneer a new kind of cancer-fighting antibody
A low-profile biotech out to shake up how the industry imagines antibody therapeutics is attracting some eyeballs today with a $103 million megaround.
IGM Biosciences is still shying away from the limelight, only divulging in a three-paragraph statement that its lead program, a CD20xCD3 bispecific, is expected to enter the clinic later this year for relapsed/refractory B cell non-Hodgkin’s lymphoma.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.